Saturday, biopharmaceutical company Allos Therapeutics, Inc. (ALTH)reported new analysis of data from pivotal PROPEL trial of FOLOTYN or pralatrexate injection in patients with relapsed or refractory peripheral T-cell lymphoma or PTCL.
The company indicated that treatment with FOLOTYN achieved an overall response rate of 29% (32 of 109 evaluable patients). Sixty-three percent of patients responded within the first cycle of therapy. Responses were durable with a median duration of response of 10.1 months. Median overall survival was 14.5 months.
"FOLOTYN is an important new therapy for patients with relapsed or refractory PTCL and for physicians who treat patients afflicted with this very aggressive cancer," said Owen O'Connor, principal investigator in the PROPEL study of FOLOTYN.
The Westminster, Colorado-based company said FOLOTYN is the first and only drug approved by the U.S. Food And Drug Administration for this indication and represents a new treatment option for patients with relapsed or refractory PTCL. FOLOTYN has been available to patients in the U.S. since October 2009.
ALTH closed Friday's regular trading at $6.62, up $0.16 or 2.48%, on a volume of about 1.39 million shares. In the after hours, the stock further gained $0.12 or 1.81% and traded at $6.74.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.